Merging Traditional Therapeutics with Psychedelic Research
Silo Pharma Inc. (OTCQB: SILO) is a development-stage biopharmaceutical company focused on identifying assets to license and fund research that could be transformative to the well-being of patients and the health care industry.
Sign up to receive investor information, corporate updates and contact from the company:
Identify target assets to license, partner with world-class organizations, target FDA designations and partner with big pharmaceutical companies.
Building out an industry-leading scientific advisory board, building IP through research and innovation, and targeting rare neurological diseases.
CEO Eric Weisblum has over 25 years of Wall Street experience and is joined by two experienced board members and three leading scientific advisors.
Silo Pharma has already licensed patents, entered into sponsored research agreements and began work with university researchers.